Kidney cancer, ESMO 2016

ESMO Copenhagen 2016: a lung cancer ‘grand cru’

My personal highlights of ESMO 2016

Results of several clinically relevant studies were presented at the 2016 Annual Meeting of the European Society of Medical Oncology (ESMO). This article summerizes the personal highlights of three medical oncologists in their respective areas of expertise.

Prostate cancer: ESMO Consensus Conference

s was at the discretion of the groups, but greater reliance was placed on peer-reviewed publications. All relevant scientific literature, as identified by the experts, was considered. A systematic literature search was not carried out. The recommendations from each group were then presented to all the experts and discussed, and a consensus was reached. The ‘Infectious Diseases Society of Americ...

Management of cancer pain: ESMO clinical recommendations.

Over 80% of cancer patients with advanced metastatic disease suffer pain caused mostly by direct tumor infiltration. Pain undermines quality of life considerably and is a clinically important indicator of tumor progression. Cancer pain may be acute or chronic and should be addressed accordingly. Approximately 20% of pain in cancer patients may be attributed to the effects of surgery, radiothera...

BRCA in breast cancer: ESMO clinical recommendations.

Familial susceptibility to breast cancer accounts for 25% of all breast cancer cases. In familial breast cancer, mutations in the BRCA1, BRCA2, CHEK2, TP53 and PTEN genes account for 5–10% of breast and ovarian cancer cases overall. The prevalence of BRCA1 or BRCA2 mutations varies considerably between ethnic groups and geographical areas. Populationspecific mutations have been described in Ice...